Preliminary Program for CROI 2022

OPENING SESSION

MARTIN DELANEY PRESENTATION

WE’RE STILL HERE: HIV, AGING, AND THE INVISIBLE GENERATION

Marc Thompson, PrEPster, London, UK

The Martin Delaney Presentation recognizes the important contributions of community advocacy and engagement to HIV/AIDS research.

BERNARD FIELDS LECTURE

VACCINE STRATEGIES FOR HIV-1 AND COVID-19

Dan H. Barouch, Beth Israel Deaconess Medical Center, Boston, MA, USA

The Bernard Fields Lecture recognizes a basic scientist for important and relevant contributions to the fields of virology and viral pathogenesis.

N’GALY-MANN LECTURE

HIV RESEARCH: GENERATING EVIDENCE TO ADVANCE PUBLIC HEALTH POLICIES IN BRAZIL

Beatriz Grinsztejn, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

The N’Galy-Mann Lecture recognizes an HIV/AIDS researcher for important and relevant work in the fields of epidemiology or clinical research.

FIRESIDE CHAT WITH ROCHELLE WALENSKY

THE COVID-19 EPIDEMIC IN THE UNITED STATES: A DISCUSSION WITH DR ROCHELLE WALENSKY

Rochelle P. Walensky, Centers for Disease Control and Prevention, Atlanta, GA, USA

A special moderated discussion with Dr Walensky, the 19th Director of the Centers for Disease Control and Prevention, will focus on the US response to the COVID-19 pandemic.

CONCURRENT TECHNICAL WORKSHOPS

MONDAY PLENARY SESSION

HIV NONHUMAN PRIMATE MODELS FOR STUDIES OF VIRUS PATHOGENESIS, PERSISTENCE, AND CURE

Michaela Müller-Trutwin, Institut Pasteur, Paris, France

CHILDREN EXPOSED TO HIV, BUT UNINFECTED: EVIDENCE FOR ACTION

Andrew J. Prendergast, Queen Mary University of London, London, United Kingdom

ORAL ABSTRACT SESSIONS

• TARGETS AND BARRIERS TO VIRAL INFECTION
• MATERNAL AND CHILD HEALTH: NEW INSIGHTS INTO HEPATITIS, SARS-CoV-2, AND HIV
• MALIGNANCIES AND COMORBIDITIES: AN INCREASING BURDEN
• EVOLVING EPIDEMIOLOGY OF HIV AND SARS-CoV-2

CONCURRENT INTERACTIVE SESSIONS

VIRAL SURVIVAL STRATEGIES IN THE FACE OF HOST IMMUNE RESPONSES: IMPLICATIONS FOR VACCINES

Moderators: Guido Silvestri, Emory University and Douglas D. Richman, University of California San Diego

• UNIQUE CHALLENGES OF VACCINATING DURING A PANDEMIC – John P. Moore, Weill Cornell Medical College, New York, NY, USA
• HPV VACCINE: A SUCCESSFUL MODEL OF VACCINE-INDUCED MUCOSAL ANTIVIRAL IMMUNE RESPONSE – Margaret Stanley, University of Cambridge, Cambridge, UK
• FLU VACCINES: THE GLASS HALF-FULL – Florian Krammer, Columbia University, New York, NY, USA
• HERPES VIRUSES: VIRUSES THAT EVADE VACCINE-INDUCED HOST-IMMUNE RESPONSES – Betsy Herold, Albert Einstein College of Medicine, New York, NY, USA
• IMMUNE ESCAPE BY HIV: OLD CONCEPTS AND NEW DATA – Alexandra Trkola, University of Zurich, Zurich, Switzerland

COVID-19 TREATMENT: CONSENSUS AND CONTROVERSIES

Case presentations with a discussion by the expert panel and questions from the audience. 

Moderators: Annie Luetkemeyer, University of California San Francisco, San Francisco, CA, USA, and Rajesh T. Gandhi, Massachusetts General Hospital, Boston, MA, USA

Panelists: 

• Ghady Haidar, University of Pittsburgh, Pittsburgh, PA, USA
• Laura E. Riley, Weill Cornell Medicine, New York, NY, USA
• David Lye, National Centre for Infectious Diseases, Singapore
• Sandra Wagner-Cardoso, Instituto de Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil

(COVID-19) VACCINE MANDATES: THE PAST, THE PRESENT, AND THE WAY FORWARD

Presentations followed by a panel discussion and questions from the audience.

• VACCINE MANDATES: HISTORY IN THE UNITED STATES AND OTHER COUNTRIES – Ruth Macklin, Albert Einstein College of Medicine, New York, NY, USA
• VACCINE HESITANCY AMONG MEMBERS OF RACIAL AND ETHNIC MINORITY GROUPS – Matifadza Hlatshwayo Davis, City of St Louis Department of Health, Saint Louis, MO, USA
• LEGAL AND POLITICAL ISSUES RELATED TO VACCINE MANDATES IN THE US, AND SOLUTIONS FOR OVERCOMING THEM – Lawrence O. Gostin, Georgetown University, Washington, DC, USA

(COVID-19) VACCINE MANDATES: THE PAST, THE PRESENT, AND THE WAY FORWARD

PANEL DISCUSSION

• Carlos Del Rio, Emory University, Atlanta, GA, USA
• Adaora Adimora, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

TUESDAY PLENARY SESSION

NEW INSIGHTS INTO HIV RNA BIOLOGY

Michael Summers, University of Maryland Baltimore County, Baltimore, MD, USA

UNDERSTANDING THE EPIDEMIOLOGY OF COVID-19: A GLOBAL PERSPECTIVE

Muge Cevik, University of St Andrews, St Andrews, UK

ORAL ABSTRACT SESSIONS

• HIV RESERVOIRS AND CURE STRATEGIES
• TUBERCULOSIS, OPPORTUNISTIC INFECTIONS, AND HEPATITIS
• HIV PREVENTION: FROM THE BENCH TO POPULATION
• GLOBAL PERSPECTIVES ON HIV TESTING, TREATMENT, AND PREVENTION
• SARS-CoV-2 ANTIVIRALS AND OUTCOMES

CONCURRENT INTERACTIVE SESSIONS

LONG COVID: FROM BENCH TO BEDSIDE AND BEYOND

Moderators: Galit Alter, Ragon Institute of MGH, MIT and Harvard and Karine Lacombe, Sorbonne Université

Presentations followed by a panel discussion and questions from the audience.

• SESSION OVERVIEW: PUTTING LONG COVID IN CONTEXT – Steven G. Deeks, University of California San Francisco, San Francisco, CA, USA
• THEMES IN NEUROLOGY – Avindra Nath, National Institutes of Health, Bethesda, MD, USA
• THEMES IN VIROLOGY – Susan R. Weiss, University of Pennsylvania, Philadelphia, PA, USA
• THEMES IN IMMUNOLOGY – Akiko Iwasaki, Yale University, New Haven, CT, USA

WHAT WILL IT TAKE TO INCREASE PEP AND PrEP USE FOR ADOLESCENT GIRLS AND YOUNG WOMEN AT RISK?

Moderators: Susan P. Buchbinder, San Francisco Department of Public Health and Moses R. Kamya, Makerere University College of Health Sciences

Presentations followed by a panel discussion and questions from the audience.

• GLOBAL PrEP UPTAKE IN ADOLESCENT GIRLS AND YOUNG WOMEN – Rachel Baggaley, World Health Organization, Geneva, Switzerland
• EXPERIENCE WITH OFFERING PEP ALONGSIDE PrEP – James Ayieko, Kenya Medical Research Institute, Nairobi, Kenya
• PrEP IMPLEMENTATION IN ADOLESCENT GIRLS AND YOUNG WOMEN – Nicolette Naidoo, Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
• PrEP IMPLEMENTATION IN YOUNG SEX WORKERS IN ZIMBABWE – Primrose Matambanadzo, Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe

WEDNESDAY PLENARY SESSION

NEW ANTIRETROVIRALS AND THE FUTURE OF HIV TREATMENT AND PREVENTION

Chloe Orkin, Queen Mary University of London, London, United Kingdom

PAST AND FUTURE OF HIV VACCINES

Mark Feinberg, International AIDS Vaccine Initiative (IAVI), Amsterdam, Netherlands

ORAL ABSTRACT SESSIONS

• IMMUNE RESPONSES TO HIV AND SARS-CoV-2 IN TREATMENT, PREVENTION, AND PATHOGENESIS
• CROSSING THE CNS BORDER: HIV, SIV, AND SARS-CoV-2
• HIV ANTIVIRALS AND OUTCOMES
• SHIFTING PARADIGMS IN HIV TESTING

CONCURRENT INTERACTIVE SESSIONS

CHIMERIC ANTIGEN RECEPTORS (CARs): WHAT’S NEXT?

Moderators: Richard A. Koup, National Institute of Allergy and Infectious Diseases, and James Hoxie, University of Pennsylvania

Presentations followed by a panel discussion and questions from the audience.

• NEW AND IMPROVED T CELL CARs FOR HIV ERADICATION OR CONTROL – James L. Riley, University of Pennsylvania, Philadelphia, PA, USA
• GENERATING CAR T CELLS IN VIVO – Hans-Peter Kiem, Fred Hutchinson Cancer Research Center, Seattle, USA
• NATURAL KILLER CELL CARs: NEW APPROACHES TO CURE LEUKEMIA AND LYMPHOMA – Katy Rezvani, University of Texas MD Anderson Cancer Center, Houston, TX, USA
• STIMULATING CARs WITH mRNA VACCINES – Benjamin Rengstl, BioNTech, Mainz, Germany

HIV CONTROVERSIES: APPROACH TO TREATMENT-EXPERIENCED PATIENTS

Case presentations with discussion by the expert panel and questions from the audience. 

Panelists

• Joseph J. Eron, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
• Mina C. Hosseinipour, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
• Hermione Lyall, Imperial College Healthcare NHS Trust, London, UK
• Natella Rakhmanina, Children’s National Hospital, Washington, DC, USA
• Annemarie Wensing, University Medical Center Utrecht, Utrecht, Netherlands
• Timothy Wilkin, Weill Cornell Medicine, New York, NY, USA

IMPACT OF VIRAL LOAD IN TRANSMISSION AND DISEASE PROGRESSION OF SARS-CoV-2 INFECTION

Moderators: Jean-Michel Molina, University of Paris and Monica Gandhi, University of California San Francisco

Presentations followed by a panel discussion and questions from the audience.

• ROLE OF VARIANTS AND VIRAL LOAD IN SARS-CoV-2 TRANSMISSION – Arnaud Fontanet, Institut Pasteur, Paris, France
• IS SARS-CoV-2 VIRAL LOAD ASSOCIATED WITH DISEASE PROGRESSION AND RESPONSE TO TREATMENT? – Matthew Spinelli, University of California San Francisco, San Francisco, CA, USA
• ARE NEW SARS-CoV-2 VARIANTS ASSOCIATED WITH MORE SEVERE DISEASE? – Fiona Havers, Centers for Disease Control and Prevention, Atlanta, GA, USA
• VIRAL LOAD KINETICS IN PARTIALLY OR FULLY VACCINATED INDIVIDUALS INFECTED WITH SARS-CoV-2 – Annelies Wilder-Smith, London School of Hygiene & Tropical Medicine, London, UK

SYMPOSIUM

GETTING INTO SHAPE: A DEEPER LOOK AT VIRAL MATURATION

Moderators: Theodora Hatziioannou, The Rockefeller University, and Frank Kirchhoff Ulm University Medical Center

• HIV-1 MATURATION – NEW VIEWS OF AN EXTRAORDINARY METAMORPHOSIS – John Briggs, Max Planck Institute of Biochemistry, Martinsried, Germany
• NEW ROLE FOR INTEGRASE IN VIRAL MATURATION – Sebla B. Kutluay, Washington University in St Louis, Saint Louis, MO, USA
• STRUCTURE, ASSEMBLY, AND FUNCTIONAL ROLES OF THE INTASOME IN HIV REPLICATION – Dmitry Lyumkis, Salk Institute for Biological Sciences, La Jolla, CA, USA

SYMPOSIUM

INFANT POSTNATAL PROPHYLAXIS: WHY BOTHER?

Moderators: Sharon Nachman, State University of New York at Stony Brook and Tim R. Cressey, Chiang Mai University

• SETTING THE STAGE: POSTNATAL PROPHYLAXIS TO REDUCE NEW PEDIATRIC INFECTIONS – Claire Thorne, University College London, London, UK
• ANTIRETROVIRALS FOR PREVENTION: FROM ADULTS TO BABIES – Martina Penazzato, World Health Organization, Geneva, Switzerland
• SPEED DIALING NEONATES TO THE IDEAL POSTNATAL PROPHYLAXIS REGIMEN – Adrie Bekker, Stellenbosch University, Cape Town, South Africa

SYMPOSIUM

BRINGING CHOICE TO HIV PREVENTION

Moderators: Sharon L. Hillier, University of Pittsburgh Medical Center and James A. McIntyre, Anova Health Institute

• PREPARING FOR THE PLATE OF PREVENTION OPTIONS: HOW CAN WE DELIVER? – Hyman Scott, San Francisco Department of Public Health, San Francisco, CA, USA
• WHY DON’T YOU JUST USE WHAT WE TELL YOU TO USE? CHOICE IN HIV PREVENTION – Kenyon Farrow, PrEP4ALL, New York, NY, USA
• APPLYING LESSONS ON EFFICACY AND AUTONOMY FROM CONTRACEPTION TO PrEP – Dominika Seidman, University of California San Francisco, San Francisco, CA, USA

SYMPOSIUM

THE HIV RESERVOIR: CREATION, SELECTION, MAINTENANCE, AND REVERSAL

Moderators: Katharine J. Bar, University of Pennsylvania, and Nicolas Chomont, Université de Montréal

• THE HIV-1 PROVIRAL LANDSCAPE: WHAT HAVE WE LEARNED? – Sarah Palmer, The Westmead Institute for Medical Research, Westmead, Australia
• ROLE OF SELECTION PRESSURES AND IMMUNE RESPONSES IN SHAPING THE PERSISTENT RESERVOIR – Francesco R. Simonetti, Johns Hopkins University, Baltimore, MD, USA
• NOVEL IMMUNOTHERAPY-BASED CURE INTERVENTIONS – Mirko Paiardini, Emory University, Atlanta, GA, USA

SYMPOSIUM

TUBERCULOSIS: NEW STRATEGIES IN THE TREATMENT OF THE WORLD’S OLDEST EPIDEMIC

Moderators: Constance A. Benson, University of California San Diego and William J. Burman, Denver Public Health

• TREATMENT SHORTENING FOR DRUG-SUSCEPTIBLE TB: WHERE ARE WE AND WHAT’S NEXT? – Susan Dorman, Medical University of South Carolina, Charleston, SC, USA
• A NEW ERA FOR TREATMENT OF MULTI-DRUG RESISTANT TUBERCULOSIS – David Moore, London School of Hygiene & Tropical Medicine, London, UK
• THE PROMISE OF NEW DRUGS AND LONG-ACTING INJECTABLES FOR TB TREATMENT AND PREVENTION – Eric L. Nuermberger, Johns Hopkins University, Baltimore, MD, USA

SYMPOSIUM

SEXUALLY TRANSMITTED INFECTIONS: REVERSING THE TIDE

Moderators: Connie L. Celum, University of Washington and Jonathan Mermin, Centers for Disease Control and Prevention

• THE STATE OF STI EPIDEMICS AND RESPONSE IN THE UNITED STATES – Leandro Mena, Centers for Disease Control and Prevention, Atlanta, GA, USA
• CURRENT AND FUTURE RESEARCH IN STI VACCINES – Sinead Delany-Moretlwe, Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
• SEXUALLY TRANSMITTED INFECTIONS PROPHYLAXIS, IS THIS THE ANSWER? – Elizabeth A. Bukusi, Kenya Medical Research Institute, Nairobi, Kenya

SYMPOSIUM

IMMUNE PROTECTION IN THE FIELD: RAISING THE STAKES

Moderators: Penny Moore, University of the Witwatersrand and Huldrych F. Günthard, University Hospital Zurich

• LESSONS LEARNED FROM THE AMP TRIAL: IS THE GLASS HALF FULL? – Carolyn Williamson, University of Cape Town, Cape Town, South Africa
• PUSHING THE ENVELOPE: mRNA VACCINES FOR COVID-19, HIV, AND OTHER PATHOGENS – Drew Weissman, University of Pennsylvania, Philadelphia, PA, USA
• JUMP-STARTED IMMUNE RESPONSE: NOW, HOW TO TEACH BREADTH? – William R. Schief, Scripps Research Institute, La Jolla, CA, USA

SYMPOSIUM

HIV AND AGING

Moderator: Peter W. Hunt, University of California San Francisco

• CLINICAL EPIDEMIOLOGY OF AGING AND COMORBIDITY WITH HIV INFECTION: A GLOBAL PERSPECTIVE – Mark Siedner, Harvard Medical School, Boston, MA, USA
• POTENTIAL BIOLOGIC MECHANISMS OF AGING IN HIV – Nicholas Funderburg, The Ohio State University, Columbus, OH, USA
• INTEGRATING FRAILTY AND FUNCTIONAL OUTCOMES INTO CLINICAL TRIALS – Kristine Erlandson, University of Colorado, Denver, CO, USA
• Panelist – Jules Levin, National AIDS Treatment Advocacy Project, New York, NY, USA
• Panelist – Venita Ray, Positive Women’s Network, Oakland, CA, USA

SYMPOSIUM

HIV PREVENTION IN SPECIAL POPULATIONS

Moderators: Jessica E. Justman, Columbia University and Raphael J. Landovitz, University of California Los Angeles

• A COMPREHENSIVE APPROACH TO HIV PREVENTION IN PEOPLE WHO USE SUBSTANCES – Adam W. Carrico, University of Miami, Miami, FL, USA
• TAILORING HIV PREVENTION STRATEGIES FOR THE UNIQUE NEEDS OF TRANSGENDER AND NONBINARY PEOPLE – Sari L. Reisner, Brigham and Women’s Hospital, Boston, MA, USA
• HIV PREVENTION APPROACHES TAILORED TO INDIVIDUALS ENGAGED IN SEX WORK – Frances Cowan, Liverpool School of Tropical Medicine, Harare, Zimbabwe